FLUIDDA
FLUIDDA, founded in 2005 in Belgium, develops Functional Respiratory Imaging (FRI) combining HRCT scans and computational fluid dynamics for patient-specific respiratory analysis. The company serves pharmaceutical/biotech clients via CRO services and physicians through its FDA-cleared Broncholab diagnostic platform.
- Company typePrivate
- Founded2005
- HeadquartersKontich, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What FLUIDDA does
FLUIDDA (Fluidda NV) is a Belgian-founded (2005) medical technology and contract research organization that develops and commercializes Functional Respiratory Imaging (FRI), a proprietary methodology that combines high-resolution computed tomography (HRCT) scans with aerospace-engineered computational fluid dynamics (CFD) to produce patient-specific, regional biomarkers of the lungs and airways. These biomarkers — including airway resistance, ventilation mapping, lobar volume, emphysema quantification, blood vessel volume (BV5, BV5_10), and aerosol deposition — are used both as clinical-trial endpoints and as diagnostic inputs. The company monetizes FRI through two interlocking revenue streams: (i) CRO services for pharmaceutical and biotech sponsors (delivery optimization, clinical trial support, regulatory/bioequivalence pathway services, and scientific visualization) sold via multi-year, quote-based enterprise contracts, and (ii) a regulated medical device product, the Broncholab platform (FDA 510(k) cleared March 2020, CE marked June 2022, ISO 13485:2016 certified 2022), which delivers FRI parameters to radiologists and pulmonologists through an online portal on a subscription basis.
The company also operates a deep-learning module, RespiNet, launched in February 2023, that automates segmentation of lung lobes and airway trees in thin-slice CT, and applies machine-learning models that reportedly predict Bronchiolitis Obliterans Syndrome after lung transplantation with 85% accuracy. FLUIDDA serves a primarily enterprise customer base that includes TEVA, Novartis, Cipla, Respivant, and Merck, and runs clinical operations across approximately 60 countries through a network of roughly 500 clinical trial hospitals, with offices in Belgium (Kontich, headquarters), the United States (New York, Los Angeles), Portugal (Lisbon), and Singapore. Strategic partnerships include an exclusive 2022 collaboration with Nanopharm (an Aptar Pharma company) to enable alternative bioequivalence pathways for orally inhaled drug products, and a 2019 Asia/Pacific alliance with KreivoHealth. On 13 November 2025, FLUIDDA was acquired by Banook, a global provider of centralized cardiac safety, central imaging, and clinical endpoint management services, becoming a subsidiary within that group.
FLUIDDA firmographics
Firmographics- Name
- FLUIDDA
- Legal name
- Fluidda NV
- Website
- https://fluidda.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- FLUIDDA, founded in 2005 in Belgium, develops Functional Respiratory Imaging (FRI) combining HRCT scans and computational fluid dynamics for patient-specific respiratory analysis. The company serves pharmaceutical/biotech clients via CRO services and physicians through its FDA-cleared Broncholab diagnostic platform.
- Ownership category
- akta.pro rank
FLUIDDA industry classification
Industry- Product category
- Medical Imaging Software
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industries
- Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC)
Keywords
Where FLUIDDA is headquartered
LocationHeadquarters
- HQ city
- Kontich
- HQ country
- Belgium
- HQ region
- Europe
Offices5 records
Markets served
FLUIDDA business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CRO Services - Clinical Trials: Fluidda provides contract research services to pharmaceutical and biotech companies for respiratory drug development and medical device development. Services include delivery optimization, clinical trial support, and scientific visualization. They offer turnkey services tailored to client needs in collaboration with dedicated partners.
- Broncholab Platform (Medical Device): FDA-cleared and CE-certified diagnostic respiratory support tool for radiologists and pulmonologists. Provides quantitative FRI parameters for clinical diagnosis and monitoring of respiratory diseases.
- Regulatory Pathway Services: Services to help accelerate FDA approvals for orally inhaled generic products via alternative bioequivalence pathways, combining FRI with Nanopharm's SmartTrack platform for in-vitro/in-silico bioequivalence demonstrations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | CRO Services - Delivery Optimization |
| Other | Multi-year contract | CRO Services - Clinical Trials |
| Subscription | Annual | Broncholab Clinical Platform |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
FLUIDDA product offering
Product offeringCore offering
FLUIDDA develops and applies Functional Respiratory Imaging (FRI), a proprietary technology that combines High-Resolution Computed Tomography (HRCT) scans with Computational Fluid Dynamics (CFD) to produce patient-specific 3D respiratory models and quantitative biomarkers. The company sells the FDA-cleared and CE-certified Broncholab medical device platform to physicians for clinical diagnosis and monitoring of respiratory diseases, and provides contract research services to pharmaceutical and biotech companies to accelerate and de-risk respiratory drug and medical device development.
Product overview
Fluidda operates as both a CRO services company and medical technology developer, offering its proprietary Functional Respiratory Imaging (FRI) technology as the core platform. FRI combines HRCT scans with computational fluid dynamics (CFD) to provide patient-specific respiratory analysis. The product portfolio includes: Broncholab (FDA-cleared and CE-marked medical device platform for clinical diagnosis and monitoring), RespiNet (deep learning segmentation model for automated CT analysis), and three CRO service modules (Delivery Optimization, Clinical Trials, and Scientific Visualization) that leverage FRI technology to accelerate respiratory drug and device development.
Differentiator
Problem solved
Functional benefit
Brands
- Broncholab: FDA-cleared and CE-certified respiratory imaging platform that provides Functional Respiratory Imaging (FRI) parameters to physicians via an online platform to assist in diagnosing and monitoring of respiratory diseases.
Products and services
- Broncholab FDA-cleared and CE-marked medical device platform that delivers Functional Respiratory Imaging (FRI) parameters to physicians via an online portal to assist in diagnosing and monitoring respiratory diseases such as COPD, asthma, ILD, and pulmonary hypertension, including blood vessel measurements (BV5, BV5_10) for detecting pulmonary vascular remodeling.
- RespiNet Deep learning model for automated segmentation of lung lobes and airway tree in volumetric thin-slice CT scans, enabling automated analysis of lung structures for use in FRI pipelines and respiratory clinical research.
- CRO Respiratory Clinical Trial Services Turnkey contract research services using Functional Respiratory Imaging biomarkers to accelerate respiratory drug and medical device clinical trials, including drug delivery optimization, clinical trial support (with up to 16 times fewer patients required), and scientific visualization of study results. Sold as multi-year engagements to enterprise pharmaceutical and biotech clients.
- Inhaled Drug Bioequivalence Pathway Services Regulatory pathway services that combine FLUIDDA's FRI platform with Nanopharm's SmartTrack in-vitro/PBPK platform to support alternative bioequivalence pathways for orally inhaled generic drug products, helping pharmaceutical clients accelerate FDA approvals.
Quantifiable outcome
- Up to 16 times fewer patients needed to obtain clinically significant results in clinical trials
- +3 more outcomes
Companies that use FLUIDDA
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
FLUIDDA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature5 records
FLUIDDA partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship/core and minor.
- Banookflagship/coreBanook, a leading global provider of centralized cardiac safety, central imaging and clinical endpoint management services, acquired Fluidda. The acquisition broadens Banook's expertise into respiratory clinical research and advanced imaging analytics, combining Fluidda's FRI platform with Banook's operational excellence in endpoint management.
- Nanopharm (Aptar Pharma)flagship/coreContinued exclusive collaboration between Nanopharm and Fluidda to enable alternative bioequivalence pathways for orally inhaled drug products. Creates unique in-vitro in-silico platform combining SmartTrack with FRI technology.
- Nanopharm (Aptar Pharma)flagship/coreExclusive collaboration to help accelerate regulatory pathway for orally inhaled products. Combining Fluidda's FRI (Functional Respiratory Imaging) platform with Nanopharm's SmartTrack platform for in-vitro/in-silico bioequivalence studies. First potential approval of OIDP using alternative bioequivalence approach pending.
- COVID-19 Consortium MembersminorConsortium for sharing insights into mode of action of COVID-19 virus. Members include: LungBioTech, Fibrogen, Pliant, NXT, Theravance, Trudell, Galapagos, ThreeLakesFoundation, Neurimmune, MSD, AstraZeneca, Chiesi.
- KreivoHealthminorCollaboration established in 2019 for Asia/Pacific region expansion. Ernestine Chung from KreivoHealth supports Fluidda with clinical operations in Middle East, Central Asia and APAC region (ex-US and ex-EU), business development, and regulatory affairs predominantly in Singapore.
- AZ Delta HospitalminorFirst hospital to make structural use of Functional Respiratory Imaging to triage COVID-19 patients, starting November 2020. Demonstrated FRI's value in clinical triaging for optimal resource allocation.
- MedImproveminorMultidisciplinary medical center for respiratory revalidation in Kontich, Belgium. Uses Fluidda's proprietary FRI technology for patient treatment optimization. Featured in Belgian newspaper De Standaard for innovative imaging technique.
- Open Source Imaging Consortium (OSIC)minorFluidda CEO Jan De Backer and CSO Ben Lavon participate in OSIC working groups on pulmonary vascular manifestations and sequelae of COVID-19.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
FLUIDDA competitors and assessment
Company assessmentDirect peers
- VIDA Diagnostics: VIDA provides AI-driven quantitative CT lung imaging software for clinical trial services and clinical practice, directly overlapping with Fluidda's FRI offering for respiratory drug development and diagnostic support.
- Thirona: Thirona develops advanced lung image analysis software (e.g., LungQ) for CT-based quantification in respiratory disease research and clinical use, competing head-to-head with Fluidda's FRI-based analysis services.
Broad incumbents
- Banook: Banook is the strategic acquirer of Fluidda and a global provider of centralized cardiac safety, imaging, and clinical endpoint management services — directly comparable as a clinical trial CRO with imaging analytics capabilities.
- ICON plc: Global clinical CRO offering respiratory and imaging endpoint services to pharma/biotech; comparable in its CRO-services customer base even though it does not focus on Fluidda's specific FRI modality.
- IQVIA: Largest global CRO with extensive respiratory clinical trial expertise and an established imaging and real-world evidence practice; comparable to Fluidda on the customer side (top-tier pharma) rather than the technology side.
Emerging players
- Arterys: AI medical imaging cloud platform with FDA-cleared analytics for chest CT and other modalities; partial overlap with Fluidda as it brings AI-driven imaging quantification to clinical practice and trials.
- Aidoc: AI imaging platform focused on radiology workflow and triage across multiple organs; comparable as a peer AI imaging company serving hospital systems, though not focused on respiratory research endpoints.
- MeVis Medical Solutions: Provider of image processing and analysis software for CT-based lung and other diagnostic workflows, with similar use cases in clinical research and pharmaceutical trials to Fluidda's FRI platform.
Others
- Nanopharm (Aptar Pharma): Strategic partner of Fluidda and developer of SmartTrack in-vitro/PBPK modeling for orally inhaled drug products; comparable as an ecosystem participant in the OIDP bioequivalence pathway alongside FRI.
- Open Source Imaging Consortium (OSIC): Non-profit consortium advancing imaging-based diagnosis and treatment of interstitial lung diseases; Fluidda's CEO and CSO participate in OSIC working groups, making it a directly relevant industry consortium peer.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
FLUIDDA social profiles
Digital presenceFLUIDDA compliance and trust
Trust signalCompliance3 records
FLUIDDA financial estimates
Financial estimateRevenue estimate
Valuation estimate
FLUIDDA leadership team
Management profileNumber of profiles
Profiles10 records
FLUIDDA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FLUIDDA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FLUIDDA
What does FLUIDDA do?
FLUIDDA develops and applies Functional Respiratory Imaging (FRI), a proprietary technology that combines High-Resolution Computed Tomography (HRCT) scans with Computational Fluid Dynamics (CFD) to produce patient-specific 3D respiratory models and quantitative biomarkers. The company sells the FDA-cleared and CE-certified Broncholab medical device platform to physicians for clinical diagnosis and monitoring of respiratory diseases, and provides contract research services to pharmaceutical and biotech companies to accelerate and de-risk respiratory drug and medical device development.
Is FLUIDDA a public or private company?
FLUIDDA is a private company. It is classified as corporate owned and is currently acquired.
When was FLUIDDA founded?
FLUIDDA was founded in 2005. It employs 11 to 50 people.
Where is FLUIDDA based?
FLUIDDA is headquartered in Kontich, Belgium, in the Europe region.
How does FLUIDDA make money?
Three revenue lines are on record. CRO Services - Clinical Trials are the primary driver. The others are broncholab Platform (Medical Device) and regulatory Pathway Services.
Who are FLUIDDA's main competitors?
Direct peers on record are VIDA Diagnostics and Thirona. Broad incumbents are Banook, ICON plc and IQVIA. Emerging players are Arterys, Aidoc and MeVis Medical Solutions. Others are Nanopharm (Aptar Pharma) and Open Source Imaging Consortium (OSIC).
Does FLUIDDA have an API?
No public API is recorded for FLUIDDA.
What industry is FLUIDDA in?
FLUIDDA's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLAHABAI, Imaging Informatics & Workflow (PACS/RIS/VNA). Its NAICS code is 3391 and its SIC code is 3841.